<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03494920</url>
  </required_header>
  <id_info>
    <org_study_id>NTA1601</org_study_id>
    <nct_id>NCT03494920</nct_id>
  </id_info>
  <brief_title>DIRECT-SAFE: A Randomized Controlled Trial of DIRECT Endovascular Clot Retrieval Versus Standard Bridging Thrombolysis With Endovascular Clot Retrieval</brief_title>
  <official_title>DIRECT-SAFE: A Randomized Controlled Trial of DIRECT Endovascular Clot Retrieval Versus Standard Bridging Thrombolysis With Endovascular Clot Retrieval Within 4.5 Hours of Stroke Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuroscience Trials Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Florey Institute of Neuroscience and Mental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuroscience Trials Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a multicentre, prospective, randomized, open label, blinded endpoint
      (PROBE) phase 3 trial (2 arm with 1:1 randomization) in ischemic stroke patients within 4.5
      hours of stroke onset. Randomised patients will be stratified for site of baseline arterial
      occlusion into one of three groups: 1. internal carotid artery (ICA) 2. middle cerebral
      artery (MCA) 3. basilar artery (BA). Patients will be randomised to either bridging
      intravenous thrombolysis with endovascular clot retrieval (ECR), or direct endovascular clot
      retrieval.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DIRECT-SAFE trial will include patients with acute ischemic stroke, who are ≥18 years of
      age and are eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset.
      Patients will be assessed for large vessel occlusion to determine their eligibility for
      randomization into the trial. Eligible vessel occlusions include the internal carotid artery,
      basilar artery or middle cerebral artery (M1 or M2). Patients will be consented after large
      vessel occlusion is confirmed based on standard care multimodal imaging.

      Patients will be recruited in Australia and New Zealand, China, Taiwan and Europe.
      Randomisation either direct to ECR or standard thrombolytic therapy and ECR shall be in a 1:1
      ratio.

      All patients will have a multimodal MR (or CT/CTP at investigator's discretion if MRI not
      possible) at 18 to 30 hours post treatment to assess reperfusion, recanalization, ischemic
      core growth and hemorrhagic transformation. Final follow up will occur at Day 90.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomised to either direct endovascular clot retrieval or to bridging intravenous thrombolysis with endovascular clot retrieval.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinded core laboratory adjudications of the primary outcome. NIHSS and mRS (secondary outcomes) performed by blinded assessor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale (mRS)- ordinal analysis</measure>
    <time_frame>3 months</time_frame>
    <description>Modified Rankin Scale (mRS) 0-2 or no change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale (mRS)- ordinal analysis</measure>
    <time_frame>3 months</time_frame>
    <description>mRS 0-1 or no change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>3 months</time_frame>
    <description>Death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic reperfusion</measure>
    <time_frame>Baseline</time_frame>
    <description>Proportion of patients with good angiographic reperfusion (mTICI 2b-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial haemorrhage (sICH)</measure>
    <time_frame>24 hours</time_frame>
    <description>Proportion of patients with sICH</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">780</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Direct endovascular clot retrieval</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Endovascular clot retrieval (ECR) within 4.5 hours stroke</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bridging thrombolysis followed by ECR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intravenous tPA (at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour) followed by ECR</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Direct endovascular clot retrieval</intervention_name>
    <description>Direct endovascular clot retrieval within 4.5 hours of stroke onset</description>
    <arm_group_label>Direct endovascular clot retrieval</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bridging thrombolysis followed by ECR</intervention_name>
    <description>Bridging thrombolysis followed by ECR within 4.5 hours of stroke onset</description>
    <arm_group_label>Bridging thrombolysis followed by ECR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients presenting with acute ischemic stroke eligible using standard criteria to
             receive IV thrombolysis within 4.5 hours of stroke onset

          2. Patient's age is ≥18 years

          3. Intra-arterial clot retrieval treatment can commence (groin puncture) within 6 hours
             of stroke onset.

          4. Arterial occlusion on CTA or MRA of the ICA, M1, M2 or basilar artery

        Exclusion Criteria:

          1. Intracranial hemorrhage (ICH) identified by CT or MRI

          2. Rapidly improving symptoms at the discretion of the investigator

          3. Pre-stroke mRS score of ≥ 4 (indicating previous disability)

          4. Hypodensity in &gt;1/3 MCA territory on non-contrast CT

          5. Contra indication to imaging with contrast agents

          6. Any terminal illness such that patient would not be expected to survive more than 1
             year

          7. Any condition that, in the judgment of the investigator could impose hazards to the
             patient if study therapy is initiated or affect the participation of the patient in
             the study.

          8. Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Mitchell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Yan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernard Yan, MD</last_name>
    <phone>039349 2477</phone>
    <email>bernard.yan@mh.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michele Sallaberger</last_name>
    <phone>0438471423</phone>
    <email>michele.sallaberger@florey.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Worthington</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alan McDougall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ferdi Miteff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Krause, A/Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Martin Krause, A/Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter Bailey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Timothy Kleinig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Henry Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Yan</last_name>
    </contact>
    <investigator>
      <last_name>Bernard Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>April 29, 2018</last_update_submitted>
  <last_update_submitted_qc>April 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Cerebral Infarction</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Brain Infarction</keyword>
  <keyword>Brain Ischemia</keyword>
  <keyword>Tissue Plasminogen Activator</keyword>
  <keyword>Plasminogen</keyword>
  <keyword>Fibrinolytic Agents</keyword>
  <keyword>Fibrin Modulating Agents</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

